Related Experiment Videos
Nonpeptide angiotensin II receptor antagonists
P B Timmermans1, D J Carini, A T Chiu
1Medical Products Department, E.I. du Pont de Nemours & Company, Wilmington, Delaware 19880-0400.
American Journal of Hypertension
|August 1, 1990
Summary
Researchers developed novel nonpeptide angiotensin II receptor antagonists. These compounds offer improved stability and oral activity, representing a new therapeutic option for managing the renin-angiotensin system.
Area of Science:
- Pharmacology
- Cardiovascular Research
- Drug Discovery
Background:
- Current angiotensin II (AII) receptor antagonists are peptides with limitations like poor stability and lack of oral activity.
- Interfering with the renin-angiotensin system (RAS) at the AII receptor is a direct therapeutic strategy.
Purpose of the Study:
- To characterize novel nonpeptide angiotensin II receptor antagonists.
- To evaluate their selectivity, efficacy, and pharmacokinetic properties.
Main Methods:
- Characterization of N-benzylimidazoles as selective AII receptor antagonists.
- Chemical modification to enhance affinity and oral activity (EXP6155, EXP6803, EXP7711, EXP9654).
- In vitro and in vivo assays to assess competitive antagonism, receptor binding, and blood pressure reduction in hypertensive models.
Main Results:
- Developed N-benzylimidazoles with weak to potent AII receptor antagonist activity.
- Achieved significant improvements in receptor affinity and oral bioavailability with modified compounds.
- Demonstrated competitive antagonism of AII effects and sustained blood pressure reduction in vivo without affecting heart rate.
Conclusions:
- Nonpeptide N-benzylimidazoles are selective, competitive AII receptor antagonists.
- These compounds exhibit favorable properties, including oral activity and lack of agonistic effects.
- This new class of drugs expands therapeutic options for modulating the renin-angiotensin system.